Lilly’s Hopes For Tabalumab Now Rest In Lupus, Myeloma Settings
This article was originally published in Pharmaceutical Approvals Monthly
The company terminates all late-stage development of the anti-B cell antibody in rheumatoid arthritis due to lack of efficacy. Ongoing studies in lupus and multiple myeloma are expected to begin reporting in 2014.
You may also be interested in...
Lilly is making major bets on the oncology and diabetes drugs in its late-stage pipeline in hopes that these assets will fill the hole left by Zyprexa, and soon Cymbalta.
Lilly has stopped one Phase III rheumatoid arthritis trial for its anti-BAFF antibody tabalumab and ceased enrollment in two others after a mid-term analysis revealed a lack of efficacy, but the company is soldiering on with a Phase III program in lupus erythematosus.
There are 18 people on the committee that will issue the first recommendations on COVID-19 vaccine development and licensure. Among the experts are a University of Michigan epidemiologist who will serve as acting chairman and seven temporary voting members, two of whom required conflict-of-interest waivers.